News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

17 January 2023 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

27 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

20 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Issuance of Shares from Authorized Capital

13 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Executive Leadership Team Changes

8 December 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

16 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

14 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

8 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

7 November 2022 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022

Tuesday, September 13, 2022
1:30pm EDT

Listen to Webcast

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

LifeSci Advisors, LLC
Irina Koffler
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +1-646-970-4681

Latest News

Corporate News

Archive

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

Relief Therapeutics Announces Executive Leadership Team Changes

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

Events and Presentations

H.C. Wainwright 24th Annual Global Investment Conference - September 12-14, 2022

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events